The current P/E ratio of SPRY cannot be calculated, as the latest EPS of -$0.51 is negative. The most recent PE ratio recorded for ARS Pharmaceuticals was 9.96 in September 2022.
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2023 | N/A | N/A | $5.48 | -$0.57 |
2022 | N/A | N/A | $8.53 | -$0.87 |
2021 | N/A | N/A | $6.66 | -$0.7 |
2020 | N/A | N/A | $46.34 | -$11.33 |
2019 | N/A | N/A | N/A | -$36.27 |
2018 | N/A | N/A | N/A | -$29.11 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Sep 2024 | N/A | N/A | $14.5 | -$0.51 |
Jun 2024 | N/A | N/A | $8.51 | -$0.47 |
Mar 2024 | N/A | N/A | $10.22 | -$0.52 |
Dec 2023 | N/A | N/A | $5.48 | -$0.57 |
Sep 2023 | N/A | N/A | $3.78 | -$0.71 |
Jun 2023 | N/A | N/A | $6.7 | -$0.76 |
Mar 2023 | N/A | N/A | $6.51 | -$0.79 |
Dec 2022 | N/A | N/A | $8.53 | -$0.87 |
Sep 2022 | 9.96 | -78.86% | $5.28 | $0.53 |
Jun 2022 | 47.11 | N/A | $4.24 | $0.09 |
Mar 2022 | N/A | N/A | $3.51 | -$0.4 |
Dec 2021 | N/A | N/A | $6.66 | -$0.7 |
Sep 2021 | 0.61 | -90.15% | $9.98 | $16.31 |
Jun 2021 | 6.19 | N/A | $30.89 | $4.99 |
Mar 2021 | N/A | N/A | $43.63 | -$3.96 |
Stock name | PE ratio | Market cap |
---|---|---|
ORMP Oramed Pharmaceuticals Inc | 19.91 | $88.28M |
OLMA Olema Pharmaceuticals Inc | N/A | $353.53M |
OMER Omeros Corp | N/A | $529.08M |
OMGA Omega Therapeutics Inc | N/A | $8.3M |
ONVO Organovo Holdings Inc | N/A | $5.2M |
ORIC Oric Pharmaceuticals Inc | N/A | $758.59M |
SPRY ARS Pharmaceuticals Inc | N/A | $1.22B |
The current price to earnings ratio of SPRY cannot be determined, as its EPS of -$0.51 is negative.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.